# A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations

> clinical trial · VERIFIED · 2026-07-06

Status: NOT_YET_RECRUITING · Sponsor: Lingyi Biotech Co., Ltd. · Condition: Parkinson's Disease (PD)

- Company: Lingyi Biotech Co., Ltd.
- Sector: Parkinson's Disease (PD)
- Primary source: https://clinicaltrials.gov/study/NCT07685444

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.